Evaluation of HEArt invoLvement in Patients With FABRY Disease

  • End date
    Mar 24, 2032
  • participants needed
  • sponsor
    Wuerzburg University Hospital
Updated on 24 January 2021
heart failure
sudden cardiac death


This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.


Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages >50 years outlining the importance to evaluate cardiac symptoms and outcomes of patients with Fabry disease.

This study is a prospective cohort study and observes patients since 2001. Through this long-term experience and the relative high number of patients this study is suggested to help estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or heart transplantation due to terminal heart failure.

All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if informed consent is provided.

Condition Fabry's Disease, Fabry Disease, Rare Diseases, Hypertrophic Cardiomyopathy, Cardiomyopathy, Cardiomyopathy, Fabry Disease, Cardiac Variant, Fabry Disease, Fabry Disease, Cardiac Variant, Fabry Disease, Cardiac Variant, rare disease, rare disorder, hypertrophic obstructive cardiomyopathy, Fabry Disease, Cardiac Variant
Clinical Study IdentifierNCT03362164
SponsorWuerzburg University Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Fabry disease (genetically confirmed)
Signed informed consent
years and older

Exclusion Criteria

No informed consent
Withdrawal of informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note